Fianlimab (LAG-3 Inhibitor) Combined With Libtayo® (Cemiplimab) Demonstrates Greater Than 60% Response Rates In Two Independent Cohorts Of Patients With Advanced Melanoma Naïve To PD-1 Or PD-L1 Inhibitors'

  • Israel Lowy,

Press/Media

Period12 Sep 2022

Media coverage

1

Media coverage

  • TitleFianlimab (LAG-3 Inhibitor) Combined With Libtayo® (Cemiplimab) Demonstrates Greater Than 60% Response Rates In Two Independent Cohorts Of Patients With Advanced Melanoma Naïve To PD-1 Or PD-L1 Inhibitors'
    Media name/outletMENAFN -Press Releases (English)
    Country/TerritoryJordan
    Date12/09/22
    PersonsIsrael Lowy,
View all 1
View less